Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells

European Journal of Pharmacology

Volumn 345, Issue 2, 1998, Pages 213-220

  Zucker, Tom Philipp ^a   Bönisch, Detlef ^a   Hasse, Andreas ^a   Grosser, Tilo ^a   Weber, Artur Aron ^a   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cell proliferation; Coronary artery, bovine; Platelet derived growth factor; Prostacyclin; Prostaglandin E1; Smooth muscle cell

Indexed keywords

FORSKOLIN; ILOPROST; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR BB; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E1;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CORONARY ARTERY; COW; DNA SYNTHESIS INHIBITION; DRUG TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION;

ALPROSTADIL; ANIMALS; CATTLE; CELL DIVISION; CELLS, CULTURED; CORONARY VESSELS; DRUG TOLERANCE; ILOPROST; MUSCLE, SMOOTH, VASCULAR; VASODILATOR AGENTS;

EID: 0344474511     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00022-3     Document Type: Article

References (35)

1. 2 by vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 224:1996;808-814.
2. Alt U., Leigh P.J., Wilkins A.J., Morris P.K., MacDermot J. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br. J. Clin. Pharmacol. 22:1986;118-119.
3. Bachhuber B.G., Sarembock I.J., Gimple L.W., McNamara C.A., Owens G.K. Thrombin-induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am. J. Physiol. 268:1995;C1141-C1147.
4. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Coleman R.A., Smith W.L., Narumiya S. VIII. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
6. 2) responsiveness of platelets. Br. J. Pharmacol. 90:1987;501-510.
7. Fallier-Becker, P., Rupp, J., Fingerle, J., Betz, E., 1990. Smooth muscle cells from rabbit aorta. In: Piper, H.M. (Ed.), Cell culture techniques in heart and vessel research. Springer, Berlin, pp. 247-270.
8. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br. Heart J. 71:1994;7-15.
9. Grosser T., Bönisch D., Zucker T.-P., Schrör K. Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization. Agents Actions. 45 (Suppl.):1995;85-91.
10. 2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur. J. Pharmacol. 319:1997;327-332.
11. Hara S., Morishita R., Tone Y., Yokoyama C., Inoue H., Kaneda Y., Ogihara T., Tanabe T. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 216:1995;862-867.
12. Hasse A., Bönisch D., Schrör K. Gene structure and expression of a prostacyclin receptor in vascular smooth muscle cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;R19. (abstract).
13. Huttner I.I., Gwebu E.T., Panganamala R.V., Sharma H.M., Geer J.C. Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. Science. 197:1977;289-291.
14. Huwiler A., Stabel S., Fabbro D., Pfeilschifter J. Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem. J. 305:1995;777-784.
15. 2 analogue) in the atherosclerotic rabbit artery after angioplasty. J. Cardiovasc. Pharmacol. 25:1995;947-952.
16. Jaschonek K., Karsch K.R., Weisenberger H., Tidow S., Faul C., Renn W. Platelet prostacyclin binding in coronary artery disease. J. Am. Coll. Cardiol. 8:1986;259-266.
17. Jaschonek K., Faul C., Schmidt H., Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur. J. Pharmacol. 147:1988;187-196.
18. Knudtson M.L., Flintoft V.F., Roth D.L., Hansen J.L., Duff H.J. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 15:1990;691-697.
19. 2 in cultured rabbit aortic smooth muscle cells. Atherosclerosis. 71:1988;165-171.
20. 1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Atherosclerosis. 53:1984;77-82.
21. Owen, N.E., 1985. Prostacyclin can inhibit DNA synthesis in vascular smooth muscle cells. In: Bailey, J.M. (Ed.), Prostaglandins, Leukotrienes, and Lipoxins. Plenum Press, New York, pp. 193-204.
22. 1 on DNA synthesis in vascular smooth muscle cells. Am. J. Physiol. 250:1986;C584-C588.
23. Pomerantz K.B., Hajjar D.P. Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis. 9:1989;413-429.
24. Rimarachin J.A., Jacobson J.A., Szabo P., Maclouf J., Creminon C., Weksler B.B. Regulation of cyclooxygenase-2-expression in aortic smooth muscle cells. Arterioscler. Thromb. 14:1994;1021-1031.
25. Ross, R., Fuster, V., 1996. The pathogenesis of atherosclerosis. In: Fuster, V., Ross, R., Topol, E.J. (Eds.), Atherosclerosis and Coronary Artery Disease. Lippincott-Raven, Philadelphia, pp. 411-460.
26. 2 and vascular smooth muscle cell proliferation. Hypertension. 26:1995;771-780.
27. Schröder H., Schrör K. Prostacyclin-dependent cyclic AMP formation in endothelial cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;101-104.
28. 2) and atherosclerosis. In: Rubanyi, G.M., Dzau, V.J. (Eds.), The Endothelium in Clinical Practice: Source and Target of Novel Therapies. Marcel Dekker, Richmond, pp. 1-44.
29. Schwartz, S.M., Reidy, M.A., 1996. Restenosis. An assessment of factors important in arterial occlusion. In: Fuster, V., Ross, R., Topol, E.J. (Eds.), Atherosclerosis and Coronary Artery Disease. Lippincott-Raven, Philadelphia, pp. 701-714.
30. Shirotani M., Yui Y., Hattori R., Kawai C. U 61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins. 41:1991;97-110.
31. 2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon? Prostaglandins. 21:1981;49-51.
32. Uehara Y., Ishimitu T., Kimura K., Ishii M., Ikesa T., Sugimoto T. Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats. Prostaglandins. 36:1988;847-857.
33. 1, prostacyclin and ZK 36.374 stimulation. In: Schrör, K. (Eds.), Prostaglandins and Other Eicosanoids in the Cardiovascular System. Karger, Basel, pp. 273-278.
34. Willis A.L., Smith D.L., Vigo C. Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids. Prog. Lipid Res. 25:1986;645-666.
35. Wittpoth M., Bönisch D., Schrör K. Trapidil inhibits PDGF-BB and LPS-induced translocation of NFκB in vascular smooth muscle cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;R51. (abstract).